Brain sugar branching by GnT-IX sets up keratan sulfate production on O-mannose glycans
A key residue (R304) makes GnT-IX favor brain O-mannose glycans, and branching boosts keratan sulfate assembly, a possible lead for demyelination and glioma.
Riepilogo
O-mannose glycans make up roughly a third of O-glycans in the brain. A brain-specific enzyme, GnT-IX (MGAT5B), adds a branch to them, and this branching has been linked to demyelination and glioma. Until now it was unclear how GnT-IX recognizes O-mannose rather than N-glycan substrates, and what branching does downstream. Using structural modeling against its relative GnT-V, mutagenesis, and in vitro enzyme assays, the authors found that a single arginine (R304) drives GnT-IX's preference for O-mannose glycans. In GnT-IX knockout mouse brain, keratan sulfate on O-mannose glycans was significantly reduced. Enzyme assays showed that keratan sulfate-building enzymes B4GALT1, B4GALT4, and CHST1 work better on branched than linear O-mannose glycans. Branching therefore appears to provide a scaffold for efficient glycan elongation. These are preclinical, mechanistic findings.
Riepilogo Dettagliato
Glycans attached to brain proteins shape synaptic plasticity, axon regeneration, and myelination. About one-third of brain O-glycans are the O-mannose (O-Man) type. A brain-specific enzyme, GnT-IX (MGAT5B), builds the branched core M2 structure by adding a β1,6-linked GlcNAc. Earlier work linked this branching to disease: GnT-IX knockout mice remyelinate faster after chemically induced demyelination, and GnT-IX knockdown slows glioma growth in vivo. How GnT-IX selects O-Man substrates, and how branched O-Man glycans are then extended, was unknown.
The team first compared an AlphaFold2 model of GnT-IX, docked with a minimal O-Man acceptor (GlcNAcβ1-2Man-O-Thr), against the crystal structure of the related N-glycan branching enzyme GnT-V (PDB 6YJU). The enzymes share about 42% sequence identity. Candidate residues near the acceptor were swapped between the two enzymes: D299-V300-F301, R304, and H369 in GnT-IX versus F283-K284-I285, T288, and V341 in GnT-V. Soluble His-tagged enzymes were expressed in COS7 cells and purified. Activity was measured by HPLC using a chemically synthesized fluorescent O-Man acceptor (GnM-S-Flu) and a pyridylamine-labeled biantennary N-glycan (GnGnbi-PA). The product was confirmed by MALDI-TOF-MS to carry one extra GlcNAc.
Several results stood out. GnT-V had about half the activity of GnT-IX toward the O-Man substrate. Swapping the three-residue motif abolished activity in both enzymes, and single D299F and F283D mutants also reduced activity, so these residues are broadly needed for catalysis. The R304T mutation sharply reduced GnT-IX activity toward O-Man, while the reciprocal T288R mutation in GnT-V raised O-Man activity about 4-fold. R304 therefore appears central to O-Man preference, plausibly because its longer side chain suits the less bulky O-Man core. With the N-glycan substrate, GnT-IX made two products (branching on the α1,6 and α1,3 mannose arms) at much lower activity than GnT-V.
Per the abstract, the authors then examined elongation. Keratan sulfate (KS) on O-Man glycans was significantly lower in GnT-IX-knockout mouse brain, which suggests that branching promotes KS biosynthesis. In vitro assays of KS biosynthetic enzymes showed that B4GALT1, B4GALT4, and CHST1 were significantly more active on branched than on linear O-Man glycans. Branching by GnT-IX may therefore serve as a scaffold for efficient subsequent elongation and sulfation.
The work gives a molecular explanation for substrate selectivity and identifies a branching-dependent route to KS on brain O-Man glycans. It may help explain why altered branching affects remyelination and glioma, since terminal epitopes such as KS, HNK-1, LewisX, and sialic acid could mediate these effects. The findings are preclinical and mechanistic: the structural model is predicted rather than experimentally solved, assays use truncated enzymes and small synthetic acceptors, and the link from KS changes to disease phenotypes is inferred rather than tested here.
Risultati Principali
- Arginine 304 in GnT-IX is crucial for its specificity toward O-mannose glycans; the R304T mutation dramatically reduced activity.
- Converting GnT-V threonine 288 to arginine increased its O-mannose branching activity about 4-fold compared with wild type.
- Keratan sulfate on O-mannose glycans was significantly reduced in GnT-IX-knockout mouse brain.
- B4GALT1, B4GALT4, and CHST1 were significantly more active on branched than on linear O-mannose glycans.
- GnT-V showed about half of GnT-IX's activity toward O-mannose substrate, while GnT-IX had much weaker activity than GnT-V toward N-glycans.
Metodologia
Researchers compared an AlphaFold2 model of GnT-IX docked with an O-Man acceptor against the GnT-V crystal structure, then made swap and point mutants. Purified enzymes from COS7 cells were assayed by HPLC with synthetic fluorescent O-Man and N-glycan acceptors (n = 3, Tukey's test), and products were confirmed by MALDI-TOF-MS. Keratan sulfate on O-Man glycans was compared in GnT-IX-knockout versus wild-type mouse brain, and KS biosynthetic enzymes were tested on branched versus linear substrates.
Limitazioni dello Studio
The GnT-IX substrate complex is a computational AlphaFold model, not an experimental structure, and assays used truncated soluble enzymes with small synthetic acceptors. The full text supplied was truncated, so the KS knockout and elongation-enzyme findings are summarized mainly from the abstract. Links between KS changes and demyelination or glioma are inferred, not tested here.
Ti è piaciuto questo riepilogo?
Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.
Inserisci la tua email per iscriverti: